Plasma Triglyceride Extraction by The Muscle
Increased accumulation of fat into the muscles is associated with what is called insulin-resistant state, which is a pre-diabetic state. The purpose of this research is to find out how fat circulating in the blood following fat consumption is taken up by the muscles in healthy people as well as people that are insulin-resistant. The investigators are specifically interested in how a hormone called insulin is involved in this process. Findings from this research will contribute to our understanding of why insulin-resistant people have increased accumulation of fat in their muscles, and ultimately help to design appropriate interventions to prevent type 2 Diabetes.
Arms and Interventions
One group consists of insulin sensitive volunteers.
One group consists of insulin resistant volunteers.
Primary Outcome Measures
- Triglyceride extraction across the forearm [Measured during a 7-hour infusion study]
Secondary Outcome Measures
- Muscle microvascular blood volume [Selected 15-minute periods during the 7 hour infusion study]
Body mass index (BMI): < 25 kg/m2 or > 30 kg/m2;
Insulin sensitivity index (ISI): insulin-sensitive ISI ≥ 7, insulin-resistant ISI ≤ 5.
Medication or supplements known to affect either endothelial function or lipid metabolism (i.e. arginine, protein, fish oil)
Uncontrolled metabolic disease, including liver or renal disease
Atrial fibrillation, history of syncope, limiting or unstable angina, congestive heart failure, known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts
Cardiac pacemaker or other medical device implanted in the body
Pulmonary hypertension or other unstable cardiopulmonary conditions
ECG documented abnormalities or valvular disease
Low hemoglobin or hematocrit (i.e., lower than accepted laboratory values)
History of hypertension or elevated blood pressure (systolic, >140 mmHg or a diastolic, >95 mmHg)
History of hyperlipidemia or plasma triglyceride concentration >200 mg/dl
Diagnosed diabetes, or 2-h plasma glucose >200 mg/dl during an oral glucose tolerance test
Current participation in a weight-loss regimen, including extreme dietary practices
Use of anabolic steroids or corticosteroids (within 3 months)
Contacts and Locations
|1||Mayo Clinic in Arizona||Scottsdale||Arizona||United States||85259|
Sponsors and Collaborators
- Mayo Clinic
- American Diabetes Association
- Principal Investigator: Lori Roust, MD, Mayo Clinic
- Principal Investigator: Christos S Katsanos, PhD, Arizona State University/Mayo Clinic Arizona
Study Documents (Full-Text)None provided.